Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
17,18 SEK | -1,49% | +6,58% | +21,16% |
Omzet 2024 * | 104 mln. 9,57 mln. 8,93 mln. | Omzet 2025 * | 393 mln. 36,18 mln. 33,77 mln. | Marktkapitalisatie | 1,92 mld. 177 mln. 165 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -151 mln. -13,9 mln. -12,97 mln. | Nettowinst (verlies) 2025 * | -166 mln. -15,28 mln. -14,26 mln. | EV/omzet 2024 * | 15,8 x |
Nettoliquiditeiten 2024 * | 274 mln. 25,19 mln. 23,51 mln. | Nettoliquiditeiten 2025 * | 222 mln. 20,41 mln. 19,06 mln. | EV/omzet 2025 * | 4,32 x |
K/w-verhouding 2024 * |
-12,7
x | K/w-verhouding 2025 * |
-7,68
x | Werknemers | 24 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,02% |
Recentste transcriptie over Vicore Pharma Holding AB
1 dag | -1,49% | ||
1 week | +6,58% | ||
Lopende maand | +17,03% | ||
1 maand | +11,56% | ||
3 maanden | +28,79% | ||
6 maanden | +20,65% | ||
Lopend jaar | +21,16% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 09-09-23 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 01-01-17 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 16-11-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 57 | 01-01-18 | |
Director/Board Member | 66 | 01-01-18 | |
Michael Buschle
BRD | Director/Board Member | 64 | 01-01-23 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 17,18 | -1,49% | 96 148 |
23-04-24 | 17,44 | +2,95% | 160 468 |
22-04-24 | 16,94 | +3,80% | 107 729 |
19-04-24 | 16,32 | +1,49% | 186 472 |
18-04-24 | 16,08 | -0,25% | 116 848 |
uitgestelde koers Nasdaq Stockholm, 24 april 2024 om 17:29 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,16% | 176 mln. | |
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,86% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-8,49% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |